Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Inflammatory Bowel Disease
NCT04521205Phase 1Unknown
- Sponsor
- Xiamen University Zhongshan Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of fecal microbiota capsule in inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Xiamen University Zhongshan Hospital. Primary endpoint: Clinical remission at 1 year. Status: unknown.
02
Drugs
fecal microbiota capsule
03
Conditions
inflammatory bowel disease (IBD)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04521205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521205.